ArticleCell research2015
The quest for spatio-temporal control of CAR T cells.
Article in Cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Ligand-induced assembly of antibody variable fragments for the chemical regulation of biological processes.Cell chemical biology · 2025Article
- Irreversible light-activated SpyLigation mediates split-protein assembly in 4D.Nature protocols · 2024Review
- A rational blueprint for the design of chemically-controlled protein switches.Nature communications · 2021Article
- A conformation-specific ON-switch for controlling CAR T cells with an orally available drug.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.Molecular therapy oncolytics · 2019Article
- Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.Journal of hematology & oncology · 2018Review
- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.PloS one · 2018Article
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.Cancer cell · 2017Article
- Therapeutic T cell engineering.Nature · 2017Review
- Chimeric antigen receptors: driving immunology towards synthetic biology.Current opinion in immunology · 2016Review
- Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.Cell research · 2016Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptors (CARs) are synthetic receptors capable of directing potent antigen-specific anti-tumor T cell responses. A recent report by Wu et al. extends a series of strategies aiming to curb excessive T cell activity, utilizing in this instance a chemical dimerizer to aggregate antigen-binding, T cell-activating and costimulatory domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.